Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
Landos Biopharma, Inc. (LABP)
Company Research
Source: GlobeNewswire
Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into mid-2025 NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or “the Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and reported financial results for the fourth quarter and the full year ended December 31, 2023. “We were focused in 2023 on advancing the NX-13 clinical program and establishing Landos as a leader in targeting immunometabolic pathways and developing novel and first-in-class, oral therapies for autoimmune diseases,” said Gregory Oakes, President and CEO of Landos. “We continue to advance the NEXUS Phase 2 study of NX-13 in ulcerative colitis and are excited about the strong momentum we have generated.” Fourth Quarter 2023 a
Show less
Read more
Impact Snapshot
Event Time:
LABP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LABP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LABP alerts
High impacting Landos Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LABP
News
- AbbVie (ABBV) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbViePR Newswire
- SHAREHOLDER ALERT: Weiss Law Investigates Landos Biopharma, Inc.Accesswire
- Landos Biopharma, Inc. (NASDAQ: LABP) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $20.42 price target on the stock, down previously from $50.00.MarketBeat
- LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPBusiness Wire
LABP
Analyst Actions
- 4/1/24 - HC Wainwright
LABP
Sec Filings
- 4/25/24 - Form DEFM14A
- 4/16/24 - Form 10-K/A
- 4/15/24 - Form PREM14A
- LABP's page on the SEC website